Research - , Tokyo, Japan
Logomix, Inc., a Tokyo-based mammalian synthetic biology company developing artificial human cells for new therapeutics based on its pioneering Geno-Writing™ platform technology.Geno-Writing™ is Logomix's innovative genome engineering platform to write large-scale and complex messages into a genome. It will enable therapy developers to write therapeutics sequences to develop new modalities and cure serious diseases such as cancer, neurodegenerative diseases, and genetic diseases under discovery collaborations with biopharma companies.
Gmail
Google Apps
Amazon AWS